Nektar Therapeutics said a Phase 2b study for its lead immunology drug failed in severe alopecia, but executives blamed the miss on trial enrollment errors

Pfizer said it plans to start 15 new studies in obesity next year, many of them in Phase 3, as it seeks to replace about

Plus, news about: Hansoh, Caris-Genentech, Royalty, LIB, Greenwich LifeSciences, Gubra, J&J, Sprout, Tiziana and Vor. 💊 OrsoBio’s early obesity data: When combined with Lilly’s tirzepatide,

Hey, it’s Shelby. I’m back from maternity leave, during which I surprised myself by embracing health tech more than ever before. I’m admittedly a technology

Allergy Therapeutics has had its grass pollen allergy treatment Grassmuno approved in Germany, its first market, setting up a launch early next year.